Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.

Matthias AugustinP G SatorR von KiedrowskiCurdin Conrad Dimitrios Rigopoulos Marco RomanelliP-D GhislainTiago Torres Demetrios IoannidesM AassiB SchulzP Jagiellonull null

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)

Secukinumab showed high treatment persistence, sustained effectiveness and a favourable safety profile up to 3 years of follow-up in the real-world population of PsO patients observed in SERENA.

Keyphrases

end stage renal disease
ankylosing spondylitis
newly diagnosed
ejection fraction
chronic kidney disease
randomized controlled trial
systematic review
peritoneal dialysis
high intensity
early onset
patient reported outcomes